Running Head: End Stage Renal Disease and Economics
End Stage Renal Disease and Economics Julius Shakari Walden University
End Stage Renal Disease Economics
Introduction The Federal Government of the United States initiated health care transformation for patients that suffered renal failure. According to Sullivan, the Medicare Part B made facilitated the initiatives that every American citizen to be entitled to the medical coverage after a given period and without discrimination on age (D., 2010). The ESRD program has been appreciated in several occasions as a success story and earning significant criticism for creating high tax burden with increased mortality rate ("Baxter announces the launch..." 2003). Original outcomes were not clear to evaluate due to insignificant increase in the number of physicians and clinics to take care of the ESRD patients all over the country sufficiently. Before then, the discussions concerning the program were treated as options that would keep the cost of providing care low (D., 2010). The current Medicare payment is $20.3 billion and this seems to burden the taxpayers. Comparing the medical expenses on peritoneal dialysis (PD) and the traditional in center hemodialysis; apparently, the End Stage Renal Disease patients will spend less if they are under PD than SERD. However, despite these economic relief, the United States’ taxpayers, the number of PD patients has remained constant with many patient being prescribed for the in-center hemodialysis treatments ("Baxter announces the launch..." 2003). The simple way of reducing the medical expenses on the Stage Renal Disease treatment would be to increase the peritoneal dialysis, as opposed to in- center...
Please join StudyMode to read the full document